Interleukin-1β (rs 1143627 T/C) Gene Polymorphism May Increase the Risk of Developing LDD in Turkish Population
1 other identifier
observational
94
1 country
1
Brief Summary
This study aims to show the association between the Interleukin-1β (rs 1143627 T/C) gene polymorphism and the patient's pain level, radiological features, functional disability, and spinal flexibility.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 8, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 10, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 3, 2020
CompletedFirst Submitted
Initial submission to the registry
July 31, 2022
CompletedFirst Posted
Study publicly available on registry
November 1, 2022
CompletedNovember 1, 2022
July 1, 2022
7 months
July 31, 2022
October 31, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Genotyping - Interleukin-1β (rs 1143627 T/C) gene polymorphism
Genotype analysis of interleukin-1β variation was analyzed with Real-Time PCR (polymerase chain reaction) using Applied bioscience 7500 Fast-Real Time PCR machine (Applied Biosystem, Foster City, California, USA). For this analysis, we use Taq primer assay which had rs number 1143627 (Thermo Fisher Scientific, Waltham, California, USA). Reverse and forward primer sequences were used defining used for possible mutations in target variations
baseline
Visual Analog Scale - Pain Assessment
Visual Analog Scale (VAS) was used to assess the pain severity of the patients. According to VAS, for pain intensity, it is generally rated as "no pain" 0 points and "moderate pain"5, worst pain imaginable" as 10 points (100 mm scale). They were asked to mark their average pain levels by considering one week. The pain level was questioned separately during resting and activity.
baseline
Oswestry Disability Index - Functional Disability
The functional level assessment was evaluated using the Oswestry Disability Index (ODI). This scale is preferred to measure the performance of the activities necessary for daily living and to define their limitations. In this scale, consist of 10 sections are included about pain level, inactivity daily living, heavy lifting, walking, sitting, standing, sleeping, sexual life, social life and travelling. There are 6 options in each question, and the patient is asked to choose the expression of his condition.
baseline
The Range of Motion of the lumbar spine
Physiotherapist will measure the Range of Motion of the lumbar spine by using digital goniometer
baseline
Modified Schober Test - Lumbar Spine Flexibility
Physiotherapist will measure. The posterior interval between both spina iliaca was marked for measurement. After determining 10 cm above and 5 cm below the marked area, the patient was asked to perform trunk flexion while standing. The difference between the initial value and is noted in cm. The difference of 0-5 cm in the test shows that the flexion flexibility decreases, and the difference over 10 cm shows that the flexibility increases. Values between 5-10 cm are considered normal.
baseline
Secondary Outcomes (2)
Pfirrmann's grading - Total Disc Degenerative Disc Score
baseline
McNab's disc classification - Disc displacements
baseline
Study Arms (2)
Lumbar degenerative disc disease
The case group was made of 50 patients, 24 women (48%) and 26 men (52%) with several clinical symptoms suggestive of LDD and the condition confirmed by MRI.
Healthy
The control group was made of 44 healthy volunteers.
Eligibility Criteria
The study was conducted between April and November 2019. This is a two-centre study undertaken at Yeditepe University Hospital's Department of Neurosurgery and the Yeditepe Institute of Health Sciences Department of Molecular Medicine. One of the analytical research approaches used was a case/control study.
You may qualify if:
- Patients with chronic low back pain (over 3 months
- Aged 18-60 years old
- With magnetic resonance imaging (MRI) evidencing LDD with Pfirrmann classification
You may not qualify if:
- Cauda equina syndrome
- Lumbar spinal stenosis
- Spinal deformities (scoliosis, kyphosis, spondylolisthesis)
- Vertebral fractures
- Inflammatory rheumatic diseases
- Diabetic neuropathy
- Pregnancy
- Drug and alcohol dependence
- Psychiatric illness
- Oncologic diseases
- Who refuse to sign the consent form and donate a blood sample for analysis of genomic DNA.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Yeditepe University
Istanbul, Turkey (Türkiye)
Biospecimen
Interleukin 1-β (rs 1143627 T/C) Gene Polymorphism
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dilek Ünsal, M.S.c
Yeditepe University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 31, 2022
First Posted
November 1, 2022
Study Start
April 8, 2019
Primary Completion
November 10, 2019
Study Completion
April 3, 2020
Last Updated
November 1, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share